Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: High-Risk Therapy Clear all
Completed Not applicable Interventional

Methods for Managing Intrusive Thoughts

NCT03416504
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Gradual Exposure (EXP-G), Variable Exposure (EXP-V)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Not applicable Interventional

Effects of Deep Brain Stimulation (DBS) Frequency on Neural Synchrony

NCT02304848
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DBS (Deep Brain Stimulation)
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

NCT02075255
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Early Phase 1 Interventional Results available

High Frequency SARS for Neurogenic Bladder and Bowel Emptying

NCT05214378
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Finetech-Brindley Sacral Anterior Roots Stimulation System
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Syracuse, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 6, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional

Improving Mobility and Function Following Transfemoral Amputation: A Novel Approach to Reverse Volumetric Muscle Loss

NCT05929508
View directory record Official record
Conditions
Traumatic Amputation of Lower Extremity
Interventions
Ischemic Preconditioning
Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Sep 6, 2026, 1:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Healthy Blood Pressure.

NCT06442293
View directory record Official record
Conditions
Safety Issues, Tolerance
Interventions
Treatment 1, Treatment 2, Placebo
Dietary Supplement
Lead sponsor
USANA Health Sciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

NCT04487106
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Interventions
Azacitidine, Trametinib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

DaxibotulinumtoxinA for Injection for the Treatment of Plantar Fasciitis

NCT03825315
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
DAXI 80 U, DAXI 120 U, Placebo
Biological · Other
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Tucson, Arizona • Carmichael, California • Castro Valley, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 6, 2026, 1:38 PM EDT
Recruiting Phase 2 Interventional

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

NCT05489887
View directory record Official record
Conditions
Neuroblastoma
Interventions
Naxitamab
Drug
Lead sponsor
Giselle Sholler
Other
Eligibility
12 Months to 21 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2036
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 6, 2026, 1:38 PM EDT
Terminated Not applicable Interventional Results available

OCT-guided LALAK for KCN

NCT01901614
View directory record Official record
Conditions
Corneal Opacity, Keratoconus
Interventions
LALAK, IEK, Retrobulbar Block or General Anesthesia, optical coherence tomography (OCT), Topical Anesthesia, femtosecond laser
Procedure · Drug · Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 6, 2026, 1:38 PM EDT
Terminated Phase 2Phase 3 Interventional

Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation

NCT00675714
View directory record Official record
Conditions
Burns
Interventions
Stable Isotope Infusion Study, Collection of blood and tissues, Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI, Humatrope, Ketoconazole, Oxandrolone, Propranolol, Oxandrolone and propranolol combined, Humatrope and propranolol combined, Placebo, Exercise--Hospital supervised intensive exercise program, Home exercise program
Procedure · Drug · Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
Up to 80 Years
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2019
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 6, 2026, 1:38 PM EDT
Recruiting Phase 2 Interventional

Pathways Relating Amnestic MCI to a Mild Traumatic Brain Injury History

NCT05446584
View directory record Official record
Conditions
Mild Cognitive Impairment, Amnestic Mild Cognitive Disorder, Amnestic Mild Cognitive Impairment, Mild Traumatic Brain Injury, Concussion, Brain
Interventions
High Definition Transcranial Direct Current Stimulation
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
55 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NCT03515538
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Cisplatin for injection, Radiation Therapy
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00103285
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
5,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
210
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

NCT01660633
View directory record Official record
Conditions
Multiple Myeloma
Interventions
High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous Transplantation
Drug · Other
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
Up to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Chicago, Illinois • Fairway, Kansas • Worcester, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 6, 2026, 1:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

NCT05463133
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Sirolimus, Cyclophosphamide, Alemtuzumab, Busulfan, Pheripheral blood stem cells, Emapalumab-Izsg, Tociluzumab, Total Body Irradiation
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

NCT02107235
View directory record Official record
Conditions
Head and Neck Neoplasms, Carcinoma, Squamous Cell
Interventions
oral rigosertib, cisplatin, Radiotherapy
Drug · Radiation
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Aurora, Colorado • Newark, Delaware • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Not applicable Interventional

Veterans Coordinated Community Care (3C) Study

NCT05272176
View directory record Official record
Conditions
Suicide
Interventions
Coping Long Term with Active Suicide Program (CLASP)
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Little Rock, Arkansas • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 6, 2026, 1:38 PM EDT
Not listed Phase 3 Interventional

Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction

NCT01357317
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Diet counseling, Phosphorus binder
Other · Drug
Lead sponsor
Salem Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

NCT00994318
View directory record Official record
Conditions
Iron Deficiency Anaemia, Chronic Kidney Disease
Interventions
FCM (Ferric carboxymaltose) high ferritin target, FCM (Ferric carboxymaltose) low ferritin target, Oral Iron (Ferrous sulphate)
Drug
Lead sponsor
Vifor Pharma
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Early Phase 1 Interventional

CoVID-19 Plasma in Treatment of COVID-19 Patients

NCT04355897
View directory record Official record
Conditions
COVID 19
Interventions
Convalescent COVID 19 Plasma
Biological
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 6, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

NCT01270724
View directory record Official record
Conditions
CNS Germ Cell Tumor
Interventions
Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 6, 2026, 1:38 PM EDT
Not listed Phase 1Phase 2 Interventional

Single Ascending Dose Study in Participants With LCA10

NCT03872479
View directory record Official record
Conditions
Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital
Interventions
EDIT-101
Drug
Lead sponsor
Editas Medicine, Inc.
Industry
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 6, 2026, 1:38 PM EDT
Terminated Not applicable Interventional

Reducing Insulin, Growth Hormones, and Tumors

NCT03785808
View directory record Official record
Conditions
Diet Modification, Lung Cancer
Interventions
Special Diet Therapy (low-carb), Special Diet Therapy (low-fat), Special Diet Therapy (USDA control)
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2019 · Synced Sep 6, 2026, 1:38 PM EDT